RxDoctor Payments Data

Anna Marie Francisco, MD

Geriatric Medicine · Odessa, TXNPI 1962722009

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 24 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.

$1,995in general payments, 2019–2025

Across 24 payments — averaging $83.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$380
  • AstraZeneca$358
  • Lilly USA, LLC$209
  • AbbVie$207
  • Smith+Nephew$187
  • Boehringer Ingelheim$120
  • plus $535 from 8 others

What the payments were for

  • Food & beverage$1,995100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,995 in reported general payments places this provider in the 85th percentile of 275 geriatric medicine providers in Texas.

See all geriatric medicine providers in Texas

Medicare billing

Part B allowed, 2024
$34,904
Medicare patients
141
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban45$24,157
MounjaroTirzepatide13$20,006
MyrbetriqMirabegron19$14,371
TradjentaLinagliptin22$11,226
Memantine Hcl ErMemantine Hcl78$8,066
RivastigmineRivastigmine Tartrate11$1,962
Gabapentin77$1,137
Memantine Hcl18$993
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen19$866
Levothyroxine Sodium64$698
Metoprolol Succinate55$695
Escitalopram Oxalate12$653
Omeprazole40$537
Potassium Chloride27$472
Mirtazapine27$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$209$20,00613 claims
Boehringer IngelheimTradjenta$120$11,22622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 275 geriatric medicine providers in Texas.

Other geriatric medicine in Odessa

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →